Patient Home Monitoring Announces Unaudited Revenue For FY2011, Growth Figures for September 2011, and Growth Figures for Q4 ...

Patient Home Monitoring (PHM) (TSX VENTURE:PHM), a company focused on in-home
cardiology disease management services, today announced continued strong growth
figures for September 2011, Q4 FY2011 and expected revenue for FY2011 in advance
of its annual report expected to be released in early 2012.


Monthly Growth

September 2011 Meter Shipments

PHM shipped 158 meters in September 2011. PHM meter shipments in Q4 totaled 453.

At the end of each month, PHM classifies revenue into two components:



1.  Existing Patient Services. PHM generates a recurring monthly revenue
    stream from enrolled weekly testers. 
2.  New Patient Enrollment.  New patients add to the existing monthly
    revenue stream.



Once enrolled, PHM ships a meter with an expected 5-year economic life to a
patient. With this meter investment, PHM generates monthly recurring revenue by
providing weekly monitoring services to the patient.


Understanding how many meters were shipped to newly enrolled patients each month
is relevant for analyzing growth because shipment of a meter is a prerequisite
to performing INR (1) tests eligible for reimbursement (2).


Quarterly Growth

Q4 INR Tests Recorded

PHM recorded 15,194 INR tests in Q4 2011, up from 10,460 INR tests in Q3. For
the month of September 2011, PHM recorded 5,477 INR tests, illustrating
continued monthly growth.


Annual Growth

FY2011 Annual Revenue and Quarterly Revenue Growth Figures

PHM began offering revenue generating services in April 2010 on a pilot basis
and recorded FY2010 revenue of $39,209.


PHM expects FY2011 revenue of over $1,440,000(3). PHM experienced an average
quarter-over-quarter revenue growth rate of more than 65%. 


"While our revenue growth has been impressive", Said Dr. Jaime Gerber, interim
CEO of PHM, "I look forward to our 2012 fiscal year and believe we will continue
to see strong double digit revenue growth quarter-over-quarter. With the
addition of our point of care facilities we expect to yield increased patient
enrollment in home self-testing and derive additional revenue from direct clinic
management. We are poised to build significant shareholder value in the coming
year."


ABOUT PHM

PHM is a healthcare services company focused on providing home-based monitoring
services and supplies for cardiology patients. PHM's entry-point service
monitors patients on blood thinner medications such as Coumadin(R) or warfarin.
Medicare recently expanded reimbursement for this in-home service. PHM has a
unique value proposition to cardiology groups that manage patients on blood
thinners, focusing on systemization to enroll patients in PST. This unique,
systemized approach creates an opportunity for physician groups to operate more
efficiently, increasing revenue to their clinic while providing a higher
standard of care for patients. PHM plans to lever its position as a value-added
service provider to expand into other home-based services for these patients and
their referring physicians. 


Information in this news release that is not current or historical factual
information may constitute forward-looking information within the meaning of
securities laws. Implicit in this information, particularly in respect of the
future outlook of PHM and anticipated events or results, are assumptions based
on beliefs of PHM's senior management as well as information currently available
to it. While these assumptions were considered reasonable by PHM at the time of
preparation, they may prove to be incorrect. Readers are cautioned that actual
results are subject to a number of risks and uncertainties, including the
availability of funds and resources to pursue operations, decline of
reimbursement rates, dependence on few payors, possible new drug discoveries, a
novel business model, dependence on key suppliers, granting of permits and
licenses in a highly regulated business, competition, low profit market segments
as well as general economic, market and business conditions, and could differ
materially from what is currently expected.


(1) International normalized ratio ("INR") tests are used as measures of current
and future sales performance. Please refer to the "Non-GAAP Measures" section of
PHM's MDA for further discussion on these operational measures.


(2) Management does not mean to suggest or imply that shipment of meters is
equivalent to revenue. Meter shipment is a prerequisite, but not a guaranty, of
revenue. Management does not propose meter shipments as a non-GAAP financial
measurement, because there is no simple reconciliation between meter shipment
and GAAP revenue.


(3) Based on unaudited financial results.